Does Wixela cause hair loss? This is a question many patients ask when they notice changes in their hair whilst using a fluticasone propionate/salmeterol inhaler. Wixela Inhub — known in the UK primarily as Seretide or its licensed generics — is widely prescribed for asthma and COPD. Hair loss is not listed as a recognised side effect in UK regulatory documentation, but understanding why patients raise this concern, what the evidence shows, and when to seek professional advice is essential for anyone managing their respiratory health.

Fluticasone/Salmeterol Inhalers and Hair Loss: What the Evidence Shows

Hair loss is not a recognised side effect of fluticasone/salmeterol inhalers in UK SmPCs, and no established clinical link exists between these inhalers and alopecia.

Experiencing these side effects? Our pharmacists can help you navigate them →

Wixela Inhub contains fluticasone propionate (an inhaled corticosteroid, ICS) and salmeterol (a long-acting beta-2 agonist, LABA). In the UK, fluticasone propionate/salmeterol combination inhalers are most commonly prescribed as Seretide Accuhaler or Seretide Evohaler, or as licensed generic equivalents; these are the products with established UK marketing authorisations referenced in MHRA/electronic Medicines Compendium (eMC) Summaries of Product Characteristics (SmPCs). The information in this article applies to all licensed fluticasone propionate/salmeterol inhalers available in the UK. These inhalers are used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).

Many patients who notice changes in their hair whilst taking a fluticasone/salmeterol inhaler understandably wonder whether their inhaler could be responsible.

Hair loss (alopecia) is not listed as a recognised side effect in the UK SmPCs for fluticasone propionate/salmeterol inhalers. The known side effects are primarily related to the inhaled route of delivery and include oral candidiasis (thrush), hoarseness, and headache. With long-term use at higher doses, systemic corticosteroid effects — including adrenal suppression and, in some cases, Cushingoid features — can occur, as described in the relevant SmPCs and the British National Formulary (BNF). Patients with COPD should also be aware that ICS-containing inhalers carry an increased risk of pneumonia, as noted in NICE guideline NG115.

There is no established clinical link between fluticasone/salmeterol inhalers and hair loss in current UK regulatory documentation or clinical literature. Hair loss is a complex condition with many potential causes, including thyroid dysfunction, nutritional deficiencies, stress, hormonal changes, and other medicines. It is therefore important not to attribute hair changes solely to an inhaler without a thorough clinical assessment. If you have noticed unusual hair shedding or thinning since starting or changing your inhaler, this warrants discussion with a healthcare professional — but it should not prompt you to stop your inhaler without medical advice, as doing so could worsen your respiratory condition.

Not sure if this is normal? Chat with one of our pharmacists →

Why Inhaled Corticosteroids May Affect Hair in Some People

Inhaled corticosteroids have much lower systemic bioavailability than oral steroids, making steroid-related hair thinning (telogen effluvium) considerably less likely, though not entirely excludable at high cumulative doses.

To understand the theoretical basis for any potential link, it helps to consider how inhaled corticosteroids work. Fluticasone propionate acts locally within the airways to reduce inflammation. Because it is inhaled rather than taken orally or injected, systemic absorption is considerably lower than with oral corticosteroids.

Systemic absorption of inhaled fluticasone propionate occurs predominantly via the lungs (pulmonary absorption), with only a very small fraction absorbed from the gastrointestinal tract after swallowing (oral bioavailability is approximately 1%). It is the pulmonary fraction that is the main source of any systemic exposure, and this is why higher prescribed doses carry a greater risk of systemic effects.

Oral and systemic corticosteroids have been associated in case reports and clinical observations with hair thinning and telogen effluvium — a form of diffuse hair shedding in which physiological or pharmacological stress prematurely shifts hair follicles into the resting (telogen) phase. However, the evidence for this association is based largely on case reports and clinical experience rather than robust controlled trial data, and the relationship should be regarded as reported rather than definitively established. This effect is considerably less likely with inhaled corticosteroids due to their much lower systemic bioavailability compared with oral preparations.

Nevertheless, at higher prescribed doses — particularly in patients who also use nasal corticosteroid sprays or topical steroids — cumulative systemic corticosteroid exposure can increase. In such circumstances, subtle systemic effects cannot be entirely excluded, though robust clinical evidence specifically linking inhaled therapy to hair loss remains very limited. The BNF and relevant SmPCs advise that systemic effects of ICS, including adrenal suppression and Cushingoid features, are more likely at higher doses and with prolonged use.

Salmeterol, the LABA component, has no known association with hair loss. Any theoretical concern therefore centres on the corticosteroid component rather than the bronchodilator.

When to Speak to Your GP or Pharmacist

Seek GP or pharmacist advice promptly if you experience sudden, patchy, or rapidly progressive hair loss, especially if accompanied by fatigue, weight changes, or other systemic symptoms.

If you are concerned about hair loss whilst taking a fluticasone/salmeterol inhaler, it is important to seek professional advice rather than making assumptions or stopping your medication abruptly. There are several situations in which you should contact your GP or pharmacist promptly:

• Sudden or significant hair shedding that began shortly after starting or increasing the dose of your inhaler

• Patchy hair loss (which may suggest alopecia areata, an autoimmune condition unrelated to medication)

• Scalp inflammation, tenderness, redness, scaling, or scarring, which may indicate a scarring alopecia requiring prompt specialist assessment

• Rapidly progressive or extensive hair loss

• Hair loss accompanied by other symptoms such as fatigue, weight changes, skin changes, or irregular periods, which could indicate an underlying thyroid or hormonal condition

• Signs of virilisation in women (such as hirsutism, acne, or voice changes), which may suggest androgen excess

• Concerns about cumulative corticosteroid exposure, particularly if you are using multiple corticosteroid-containing products simultaneously

Your GP will typically begin with a thorough history and examination. Routine investigations for hair loss in primary care include thyroid function tests (TSH), full blood count (FBC), and serum ferritin. An androgen profile (e.g., testosterone, DHEAS) is appropriate if there are clinical features suggesting hyperandrogenism, but is not required routinely. This systematic approach, as outlined in NICE Clinical Knowledge Summaries (CKS) on alopecia, ensures that any treatable underlying cause is identified.

Referral to a dermatologist should be considered if the diagnosis is uncertain, if scarring alopecia is suspected, or if hair loss is rapidly progressive or causing significant distress. Urgent referral is warranted if scarring alopecia is suspected, as early treatment may limit permanent follicle damage.

Your pharmacist can also provide valuable guidance on your current medication regimen, check for potential interactions, and advise on whether a medicines review with your GP would be appropriate. Do not stop taking your inhaler without medical advice — uncontrolled asthma or COPD carries significant health risks, and any decision to change or discontinue treatment should always be made in partnership with a clinician.

Managing Side Effects While Continuing Your Treatment

Optimising inhaler technique, rinsing your mouth after each dose, using the lowest effective dose, and ensuring adequate nutrition are key practical steps to minimise side effects whilst continuing treatment.

For most patients, the benefits of a fluticasone/salmeterol inhaler in controlling asthma or COPD symptoms far outweigh the risk of side effects. If you are experiencing hair changes and your GP has ruled out other causes, there are several practical steps that may help whilst you continue your treatment.

Optimising your inhaler technique is an important first step. Poor technique can lead to greater deposition of the inhaled dose in the mouth and throat, increasing the amount swallowed and potentially raising systemic absorption from the gastrointestinal tract. Your GP, pharmacist, or respiratory nurse can review your technique and ensure you are using your device correctly. Rinsing your mouth and gargling with water after each dose, then spitting out is recommended: this reduces local oropharyngeal effects (such as thrush and hoarseness) and minimises the swallowed fraction of the dose. It does not, however, reduce the systemic absorption that occurs via the lungs. If you use a metered-dose inhaler (MDI) such as Seretide Evohaler, using a spacer device can improve drug delivery to the lungs and reduce oropharyngeal deposition and local side effects; spacers are not applicable to dry powder inhalers (DPIs) such as the Accuhaler. NHS guidance on inhaler technique provides device-specific advice.

Using the lowest effective dose is a core principle of inhaled corticosteroid prescribing. For asthma, this is outlined in NICE guideline NG80, which recommends regular review and step-down of ICS dose when symptoms are well controlled. For COPD, NICE guideline NG115 advises careful consideration of the indications for ICS-containing inhalers, given the associated risk of pneumonia, and recommends using the lowest effective dose.

From a hair health perspective, ensuring adequate nutrition — particularly sufficient protein, iron, zinc, and biotin — supports healthy hair growth and may help mitigate shedding regardless of its cause. Managing stress, which is itself a well-recognised trigger for telogen effluvium, is equally important. If hair loss persists and is causing significant distress, your GP may refer you to a dermatologist for specialist assessment.

MHRA Guidance and Reporting Unexpected Reactions

Unexpected reactions to fluticasone/salmeterol inhalers, including hair loss, should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK body responsible for monitoring the safety of medicines after they have been licensed. Post-marketing surveillance plays a crucial role in identifying side effects that may not have been apparent during clinical trials, particularly rare or delayed reactions.

If you believe you have experienced a side effect from your fluticasone/salmeterol inhaler — including unexpected hair loss — you are encouraged to report it through the MHRA's Yellow Card scheme, available at yellowcard.mhra.gov.uk. Healthcare professionals, patients, and carers can all submit reports. This system helps the MHRA identify patterns in adverse reactions and, where necessary, update product information or issue safety communications. Reporting does not confirm that the medicine caused the reaction, but it contributes to the broader evidence base that informs regulatory decisions.

The current UK SmPCs for licensed fluticasone propionate/salmeterol inhalers (such as Seretide Accuhaler and Seretide Evohaler), available via the eMC, do not list alopecia as a known adverse effect. Regulatory documentation is updated as new evidence emerges, and patient reports via Yellow Card are a valuable part of this process.

In summary, whilst there is no established clinical evidence that fluticasone/salmeterol inhalers directly cause hair loss, individual responses to medicines can vary. Any unexplained or distressing change in your health whilst taking a prescribed medicine deserves proper investigation. Working with your healthcare team — rather than discontinuing treatment independently — ensures both your respiratory health and your overall wellbeing are appropriately managed.

Frequently Asked Questions